Glenmede Trust Co. NA Acquires 4,342 Shares of Becton, Dickinson and Company $BDX

Glenmede Trust Co. NA increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 3.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 117,165 shares of the medical instruments supplier’s stock after acquiring an additional 4,342 shares during the period. Glenmede Trust Co. NA’s holdings in Becton, Dickinson and Company were worth $18,422,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. Steph & Co. raised its stake in shares of Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares during the last quarter. SHP Wealth Management bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $29,000. Finally, WPG Advisers LLC boosted its position in shares of Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 61 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $166.19 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The firm has a market cap of $45.79 billion, a PE ratio of 42.07, a P/E/G ratio of 11.80 and a beta of 0.21. The business has a 50 day moving average of $151.85 and a 200-day moving average of $163.64. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same period last year, the company posted $3.35 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 12.53 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BDX shares. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research report on Monday, July 6th. The Goldman Sachs Group cut their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Weiss Ratings lowered shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. UBS Group started coverage on shares of Becton, Dickinson and Company in a report on Tuesday. They issued a “buy” rating and a $190.00 target price for the company. Finally, TD Cowen dropped their price target on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research report on Monday, May 4th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $180.93.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,189 shares of company stock worth $765,661 over the last three months. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.